BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 34231532)

  • 21. A Network Meta-Analysis of Retreatment Rates following Bevacizumab, Ranibizumab, Aflibercept, and Laser for Retinopathy of Prematurity.
    Chang E; Josan AS; Purohit R; Patel CK; Xue K
    Ophthalmology; 2022 Dec; 129(12):1389-1401. PubMed ID: 35842190
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intravitreal bevacizumab in combination with laser therapy for the treatment of severe retinopathy of prematurity (ROP) associated with vitreous or retinal hemorrhage.
    Nazari H; Modarres M; Parvaresh MM; Ghasemi Falavarjani K
    Graefes Arch Clin Exp Ophthalmol; 2010 Dec; 248(12):1713-8. PubMed ID: 20582706
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The efficacy and ocular safety following aflibercept, conbercept, ranibizumab, bevacizumab, and laser for retinopathy of prematurity: a systematic review and meta-analysis.
    Chen J; Hao Q; Zhang J; Du Y; Chen H; Cheng X
    Ital J Pediatr; 2023 Oct; 49(1):136. PubMed ID: 37814332
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development of refractive error in children treated for retinopathy of prematurity with anti-vascular endothelial growth factor (anti-VEGF) agents: A meta-analysis and systematic review.
    Tan QQ; Christiansen SP; Wang J
    PLoS One; 2019; 14(12):e0225643. PubMed ID: 31790445
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Management of Retinopathy of Prematurity--Use of Anti-VEGF Therapy.
    Tran KD; Cernichiaro-Espinosa LA; Berrocal AM
    Asia Pac J Ophthalmol (Phila); 2018; 7(1):56-62. PubMed ID: 29376233
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Refractive outcomes after intravitreal injection of antivascular endothelial growth factor versus laser photocoagulation for retinopathy of prematurity: a meta-analysis.
    Kong Q; Ming WK; Mi XS
    BMJ Open; 2021 Feb; 11(2):e042384. PubMed ID: 33568373
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The German ROP Registry: data from 90 infants treated for retinopathy of prematurity.
    Walz JM; Bemme S; Pielen A; Aisenbrey S; Breuß H; Alex AF; Wagenfeld L; Schiedel S; Krohne TU; Stahl A;
    Acta Ophthalmol; 2016 Dec; 94(8):e744-e752. PubMed ID: 27197876
    [TBL] [Abstract][Full Text] [Related]  

  • 28. SHORT-TERM COMPUTER-ASSISTED QUANTIFICATION OF PLUS DISEASE AFTER TREATMENT OF TYPE 1 RETINOPATHY OF PREMATURITY WITH INTRAVITREAL BEVACIZUMAB OR RETINAL LASER PHOTOCOAGULATION.
    Cabrera MT; Chia T; Wallace DK; Ulrich JN; Freedman SF; Ding L; Gertsch KR
    Retin Cases Brief Rep; 2021 May; 15(3):314-319. PubMed ID: 30036271
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison in Retreatments between Bevacizumab and Ranibizumab Intravitreal Injections for Retinopathy of Prematurity: A Multicenter Study.
    Patel NA; Acaba-Berrocal LA; Hoyek S; Fan KC; Martinez-Castellanos MA; Baumal CR; Harper CA; Berrocal AM;
    Ophthalmology; 2023 Apr; 130(4):373-378. PubMed ID: 36396121
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Refractive Outcomes of 4-Year-old Children after Intravitreal Anti-vascular Endothelial Growth Factor versus Laser Photocoagulation for Retinopathy of Prematurity.
    Kang HG; Kim TY; Han J; Han SH
    Korean J Ophthalmol; 2019 Jun; 33(3):272-278. PubMed ID: 31179659
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anti-Vascular Endothelial Growth Factor Therapy for Primary Treatment of Type 1 Retinopathy of Prematurity: A Report by the American Academy of Ophthalmology.
    VanderVeen DK; Melia M; Yang MB; Hutchinson AK; Wilson LB; Lambert SR
    Ophthalmology; 2017 May; 124(5):619-633. PubMed ID: 28341474
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A proposal of an algorithm for the diagnosis and treatment of recurrence or treatment failure of retinopathy of prematurity after anti-VEGF therapy based on a large case series.
    Martínez-Castellanos MA; González-H León A; Romo-Aguas JC; Gonzalez-Gonzalez LA
    Graefes Arch Clin Exp Ophthalmol; 2020 Apr; 258(4):767-772. PubMed ID: 31953595
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of long-term treatment outcomes of laser and anti-VEGF therapy in retinopathy of prematurity: a multicentre study from J-CREST group.
    Murakami T; Okamoto F; Kinoshita T; Shinomiya K; Nishi T; Obata S; Ogura S; Nishihara Y; Tsukitome H; Jujo T; Ueda K; Ishii R; Oshika T
    Eye (Lond); 2023 Dec; 37(17):3589-3595. PubMed ID: 37149685
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of 5-year safety and efficacy of laser photocoagulation and intravitreal bevacizumab injection in retinopathy of prematurity.
    Murakami T; Sugiura Y; Okamoto F; Okamoto Y; Kato A; Hoshi S; Nagafuji M; Miyazono Y; Oshika T
    Graefes Arch Clin Exp Ophthalmol; 2021 Sep; 259(9):2849-2855. PubMed ID: 33744981
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prospective clinical study of two different treatment regimens of combined laser photocoagulation and intravitreal bevacizumab for retinopathy of prematurity: the Indian Twin Cities ROP Study (ITCROPS) database report number 9.
    Laveti V; Balakrishnan D; Rani PK; Mohamed A; Jalali S
    Int Ophthalmol; 2020 Dec; 40(12):3539-3545. PubMed ID: 32776299
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Low dose versus conventional dose of intravitreal bevacizumab injection for retinopathy of prematurity: a case series with paired-eye comparison.
    Han J; Kim SE; Lee SC; Lee CS
    Acta Ophthalmol; 2018 Jun; 96(4):e475-e478. PubMed ID: 27011262
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Aggressive posterior retinopathy of prematurity in two cohorts of patients in South India: implications for primary, secondary, and tertiary prevention.
    Shah PK; Subramanian P; Venkatapathy N; Chan RVP; Chiang MF; Campbell JP
    J AAPOS; 2019 Oct; 23(5):264.e1-264.e4. PubMed ID: 31521847
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of the Efficacy Between Intravitreal Aflibercept and Laser Photocoagulation in the Treatment of Retinopathy of Prematurity.
    Ekinci DY; Çelik K
    J Pediatr Ophthalmol Strabismus; 2020 Jan; 57(1):54-60. PubMed ID: 31972042
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Refractive profile of children treated with intravitreal bevacizumab for retinopathy of prematurity.
    Pawar N; Somyashree D; Meenakshi R; Maheshwari D; Mohideen S; Sithiq Uduman M
    Indian J Ophthalmol; 2023 Jun; 71(6):2561-2568. PubMed ID: 37322680
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Real-World Visual Outcomes of Laser and Anti-VEGF Treatments for Retinopathy of Prematurity.
    Gundlach BS; Kokhanov A; Altendahl M; Suh SY; Fung S; Demer J; Pineles S; Khitri M; Chu A; Tsui I
    Am J Ophthalmol; 2022 Jun; 238():86-96. PubMed ID: 34788594
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.